Johnson & Johnson Acquires New Position in Neumora Therapeutics, Inc. $NMRA

Johnson & Johnson bought a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,849,445 shares of the company's stock, valued at approximately $3,144,057. Neumora Therapeutics makes up approximately 0.0% of Johnson & Johnson's holdings, making the stock its 12th largest holding. Johnson & Johnson owned approximately 1.00% of Neumora Therapeutics at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Hsbc Holdings PLC bought a new stake in shares of Neumora Therapeutics in the 4th quarter worth approximately $27,000. Virtu Financial LLC bought a new position in Neumora Therapeutics in the 3rd quarter valued at about $31,000. Fred Alger Management LLC acquired a new stake in Neumora Therapeutics in the fourth quarter valued at approximately $40,000. Canada Pension Plan Investment Board bought a new stake in Neumora Therapeutics in the second quarter valued at $41,000. Finally, Public Employees Retirement System of Ohio bought a new position in Neumora Therapeutics in the 3rd quarter valued at $44,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock traded down $0.03 during mid-day trading on Friday, reaching $1.45. 336,285 shares of the company's stock were exchanged, compared to its average volume of 1,690,438. The business's fifty day simple moving average is $1.61 and its 200 day simple moving average is $2.09. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 1.19. Neumora Therapeutics, Inc. has a one year low of $0.83 and a one year high of $3.65. The firm has a market capitalization of $272.45 million, a PE ratio of -1.18 and a beta of 2.75.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. On average, sell-side analysts expect that Neumora Therapeutics, Inc. will post -0.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Needham & Company LLC cut their price objective on shares of Neumora Therapeutics from $8.00 to $5.00 and set a "buy" rating on the stock in a research report on Tuesday, June 16th. Weiss Ratings cut Neumora Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, August 14th. HC Wainwright reissued a "buy" rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. Wall Street Zen upgraded Neumora Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, Royal Bank Of Canada lowered their price objective on shares of Neumora Therapeutics from $7.00 to $5.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.57.

Insider Activity

In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 91,690 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1.50, for a total transaction of $137,535.00. Following the sale, the insider directly owned 48,750 shares in the company, valued at approximately $73,125. The trade was a 65.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 453,833 shares of company stock valued at $701,219. Corporate insiders own 26.94% of the company's stock.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora's product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source